AxoGen, Inc. (AXGN) CFO Jamie Mark Grooms Sells 10,300 Shares

AxoGen, Inc. (NASDAQ:AXGN) CFO Jamie Mark Grooms sold 10,300 shares of AxoGen stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $26.21, for a total transaction of $269,963.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jamie Mark Grooms also recently made the following trade(s):

  • On Thursday, February 15th, Jamie Mark Grooms sold 95,712 shares of AxoGen stock. The stock was sold at an average price of $26.84, for a total transaction of $2,568,910.08.
  • On Tuesday, December 12th, Jamie Mark Grooms sold 38,405 shares of AxoGen stock. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75.
  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80.
  • On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The stock was sold at an average price of $26.38, for a total transaction of $2,223,702.10.

AxoGen, Inc. (NASDAQ AXGN) traded up $0.50 during mid-day trading on Friday, reaching $27.40. 265,200 shares of the company’s stock traded hands, compared to its average volume of 283,558. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. AxoGen, Inc. has a 12-month low of $9.55 and a 12-month high of $31.70. The company has a market capitalization of $917.12, a price-to-earnings ratio of -68.50 and a beta of 0.12.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in AxoGen by 29.7% during the fourth quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock valued at $50,540,000 after purchasing an additional 408,596 shares during the last quarter. Vanguard Group Inc. increased its stake in AxoGen by 9.0% during the second quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after purchasing an additional 101,245 shares during the last quarter. Bank of New York Mellon Corp increased its stake in AxoGen by 34.6% during the fourth quarter. Bank of New York Mellon Corp now owns 849,993 shares of the medical equipment provider’s stock valued at $24,054,000 after purchasing an additional 218,430 shares during the last quarter. Next Century Growth Investors LLC increased its stake in AxoGen by 1.7% during the fourth quarter. Next Century Growth Investors LLC now owns 667,642 shares of the medical equipment provider’s stock valued at $18,894,000 after purchasing an additional 10,876 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in AxoGen by 63.5% during the fourth quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock valued at $18,616,000 after purchasing an additional 255,400 shares during the last quarter. Hedge funds and other institutional investors own 65.28% of the company’s stock.

A number of analysts recently issued reports on the stock. Cantor Fitzgerald set a $37.00 price target on shares of AxoGen and gave the stock a “buy” rating in a research note on Monday, January 8th. Jefferies Group assumed coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 price target for the company. William Blair assumed coverage on shares of AxoGen in a research note on Monday, February 5th. They issued an “outperform” rating for the company. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Wedbush restated a “buy” rating and issued a $27.00 price target (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $29.33.

ILLEGAL ACTIVITY WARNING: “AxoGen, Inc. (AXGN) CFO Jamie Mark Grooms Sells 10,300 Shares” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/16/axogen-inc-axgn-cfo-jamie-mark-grooms-sells-10300-shares.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply